Your browser doesn't support javascript.
loading
Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction.
Musse, Mahad; Lau, Jennifer D; Yum, Brian; Pinheiro, Laura C; Curtis, Hannah; Anderson, Timothy; Steinman, Michael A; Meyer, Markus; Dorsch, Michael; Hummel, Scott L; Goyal, Parag.
Afiliación
  • Musse M; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Lau JD; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Yum B; Texas Heart Institute, Houston, Texas.
  • Pinheiro LC; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Curtis H; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Anderson T; Division of General Medicine, Beth Israel Deaconess, Boston, Massachusetts.
  • Steinman MA; Division of Geriatrics, University of California San Francisco; San Francisco Veterans Affairs Medical Center, San Francisco, California.
  • Meyer M; University of Minnesota, Minneapolis, Minnesota.
  • Dorsch M; College of Pharmacy, University of Michigan, Ann Arbor, Michigan.
  • Hummel SL; University of Michigan Frankel Cardiovascular Center; VA Ann Arbor Health System, Ann Arbor, Michigan.
  • Goyal P; Department of Medicine, Weill Cornell Medicine, New York, New York. Electronic address: pag9051@med.cornell.edu.
Am J Cardiol ; 193: 70-74, 2023 04 15.
Article en En | MEDLINE | ID: mdl-36878055
ß-blockers are commonly used in heart failure with preserved ejection fraction (HFpEF), even in the absence of a compelling indication and despite the potential to cause harm. Identifying reasons for ß-blocker prescription in HFpEF could permit the development of strategies to reduce unnecessary use and potentially improve medication prescribing patterns in this vulnerable population. We administered an online survey regarding ß-blocker prescribing behavior to physicians trained in internal medicine or geriatrics (noncardiology physicians) and to cardiologists at 2 large academic medical centers. The survey assessed the reasons for ß-blocker initiation, agreement regarding initiation and/or continuation of ß-blockers by another clinician, and deprescribing behavior. The response rate was 28.2% (n = 231). Among respondents, 68.2% reported initiating ß-blockers in patients with HFpEF. The most common reason for initiating a ß-blocker was for treatment of an atrial arrhythmia. Notably, 23.7% of physicians reported initiating a ß-blocker without an evidence-based indication. When a ß-blocker was considered not necessary, 40.1% of physicians reported they were rarely or never willing to deprescribe. The most common reason for not deprescribing a ß-blocker when the physician felt that a ß-blocker was unnecessary was the concern about interfering with another physicians' treatment plan (76.6%). In conclusion, a significant proportion of noncardiology physicians and cardiologists report prescribing ß-blockers to patients with HFpEF, even when evidence-based indications are absent, and rarely deprescribe ß-blockers in these scenarios.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiólogos / Insuficiencia Cardíaca Límite: Humans Idioma: En Revista: Am J Cardiol Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cardiólogos / Insuficiencia Cardíaca Límite: Humans Idioma: En Revista: Am J Cardiol Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos